The treatment involves use of an existing drug normally used to treat blood pressure, and so is quite safe. The drug is a particular ACE inhibitor. ACE stands for “angiotensin I converting enzyme.” The treatment counteracts the underlying process in emphysema: loss of lung tissue, or “apoptosis.” Removal of lung tissue surgically does little to halt this process. Loss of lung tissue in emphysema appears to be due to angiotensin II, which is produced by ACE in the lung vessels. Lung vessels have much more ACE than any other organ in the body. In the patient followed the longest to date, a heavy smoker with terminal emphysema, GenoMed’s treatment provided an extra 7 years of life with good quality, despite continued smoking. This outcome far surpasses those of lung reduction surgery or any other treatment in the medical literature.
Dr. David Moskowitz, GenoMed’s Chairman and Chief Medical Officer, said, “Before Medicare starts paying for lung reduction surgery, which has not improved overall mortality in emphysema patients, it should at least consider our treatment.”
GenoMed’s treatment costs $800 a year, as compared to $60,000 for emphysema surgery. There are 2 million Americans with emphysema. In addition, GenoMed has genomic epidemiologic data that its treatment approach may delay emphysema and lung cancer, which should interest the 70 million Americans who smoke.
GenoMed, Inc. is a Next Generation Disease ManagementTM whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including HIV infection, AIDS, and autoimmune diseases. The Company has filed world-wide patent applications on its new treatments, and is eager to license them globally. GenoMed’s research results are more fully described on its website, www.genomedics.com
For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-652-0500, FAX 314-977-0042, email: email@example.com or visit us at www.genomedics.com.
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) treatments and business model. The words or phrases “would be,” “ought to,” “should,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether patients with coronavirus infection and SARS respond to this treatment approach; (b) whether we will have sufficient financing to conduct our research and development; (c) how competition from existing or new competitors will impact our business, and (d) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.